PT - JOURNAL ARTICLE AU - Beatrice Taylor AU - Suraya Mohamud AU - Emilie V Brotherhood AU - Emma Harding AU - Claire Waddington AU - Paul M Camic AU - Daniel C Alexander AU - Sebastian J Crutch AU - Joshua Stott AU - Chris Hardy AU - Neil P Oxtoby TI - How do the activities of daily living decline in people living with rarer dementias? A systematic review AID - 10.1101/2022.09.22.22280192 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.22.22280192 4099 - http://medrxiv.org/content/early/2022/09/23/2022.09.22.22280192.short 4100 - http://medrxiv.org/content/early/2022/09/23/2022.09.22.22280192.full AB - Objective To study how activities of daily living (ADLs) decline over the progressive course of rarer dementias (prevalence below 10%), in a systematic review of the literature.Methods Relevant studies were identified by searching Medline, Embase, Emcare, PsycINFO and Cinahl. The databases were searched for terms relating to (rarer dementias) AND (activities of daily living) AND (longitudinal OR cross-sectional studies), using a pre-established protocol registered with the international prospective register of systematic reviews (registration: CRD42021283302).Results A total of 579 articles were screened for relevant content, of which 20 full-text publications were included in the analysis. Nineteen studies were about rarer dementias on the frontotemporal dementia/primary progressive aphasia spectrum, and one was about posterior cortical atrophy. Long term description of decline was limited to just seven studies following patients for longer than five years. The rate of decline, sequence of symptom onset, and symptom duration were also highlighted.Conclusion Descriptions of ADL progression were inadequately long term, covering an average of 3.5 years from symptom onset, and lacked phenotypic specificity. The literature disproportionately studied dementias on the frontotemporal dementia spectrum. To facilitate better care, more longitudinal data, quantitative analyses, and development of rarer dementia-specific ADL scales is needed. Given the low prevalence of rarer dementias, big data analyses may never be applicable and so personalised medicine approaches should be pursued, including innovative possibilities in digital biomarkers such as from wearable technology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is part of the Rare Dementia Support Impact project (The impact of multicomponent support groups for those living with rarer dementias, (ES/S010467/1)) and is funded jointly by the Economic and Social Research Council (ESRC) and the National Institute for Health Research (NIHR). ESRC is part of UK Research and Innovation. The views expressed are those of the author(s) and not necessarily those of the ESRC, UKRI, the NIHR or the Department of Health and Social Care. Rare Dementia Support is generously supported by the National Brain Appeal (https://www.nationalbrainappeal.org/). BT is supported by the ESRC-funded UCL, Bloomsbury and East London Doctoral Training Partnership (UBEL-DTP) (ES/P000592/1). EH is an ESRC postdoctoral research fellow (ES/W006014/1). The NIHR UCLH Biomedical Research Centre and Wellcome Trust award 221915/Z/20/Z support DCAs work in this area. SC acknowledges support from University College London Hospitals Biomedical Research Centre. JS is supported by the UCLH NIHR Biomedical Research Centre. CJDH was supported by an RNID-Dunhill Medical Trust Pauline Ashley Fellowship (grant PA23_Hardy) and a Wellcome Institutional Strategic Support Fund Award (204841/Z/16/Z). NPO is a UKRI Future Leaders Fellow (MR/S03546X/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSystematic review - not applicable.